Clostridium Difficile Infection Treatment Market Size Worth US$ 2.28 Billion by 2034 at a CAGR Of 6.3% | Fact.MR Report
Pharmaceutical Innovations, Collaborative Research Initiatives, and Increased Awareness Driving Clostridium Difficile Infection Treatment Market GrowthRockville, MD, Jan. 23, 2025 (GLOBE NEWSWIRE) -- ...
FiercePharma4h
Teva's multiple sclerosis stalwart Copaxone gets FDA boxed warning for anaphylaxis risk
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
Pharmaceutical Technology5h
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. The US Food and Drug ...
Teva price target raised to $30 from $28 at UBS
UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...
Teva Pharmaceuticals: Promising Growth Prospects and Buy Rating Reaffirmed
Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...
Diversify Advisory Services LLC Purchases 496 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Diversify Advisory Services LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 2.5% during the fourth quarter, according to its most recent ...
The American Journal of Managed Care18h
FDA Warns of Severe Allergic Reactions With Certain Multiple Sclerosis Drugs
Today, the FDA issued a warning about the risk of anaphylaxis, a rare but life-threatening allergic reaction, linked to ...
devdiscourse19h
Global Health News: Abroad and in Focus
Recent news highlights include Hong Kong shareholders rejecting Fosun's buyout of Henlius Biotech, Abbott focusing on glucose monitors amidst currency woes, FDA warning on multiple sclerosis drugs, ...
Managed Healthcare Executive20h
FDA Adds Boxed Warning to MS Drug Copaxone
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...
JD Supra22h
Precedential Federal Circuit Decision Overturns Lack of Written Description Based on Later-Discovered Technology
On January 10, 2025, the US Court of Appeals for the Federal Circuit issued a precedential opinion in Novartis Pharmaceuticals Corp. v. Torrent ...
Corcept Therapeutics Generating Strong Revenue And Profit Growth
Corcept Therapeutics' long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant. Click here to read ...
The Pharma Letter23h
FDA warns of rare but serious allergic reaction with glatiramer
The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...